Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults

Next Previous
X
Search
Trial Profile

A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine (Primary) ; Islatravir (Primary) ; Lamivudine (Primary) ; Doravirine/lamivudine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DRIVE2Simplify
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 26 Oct 2022 Results of post hoc analysis assessing changes in total lymphocyte and lymphocyte subset counts, presented at the 16th International Congress on Drug Therapy and HIV Infection
    • 01 Sep 2022 Results published in the JAIDS
    • 02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 09-Mar-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top